TC Biopharm (Holdings) Plc (TCBP)
- Previous Close
1.5700 - Open
1.5800 - Bid 1.5100 x 200
- Ask 1.6300 x 200
- Day's Range
1.5600 - 1.6292 - 52 Week Range
0.8500 - 266.0000 - Volume
25,467 - Avg. Volume
4,598,972 - Market Cap (intraday)
4.985M - Beta (5Y Monthly) 0.33
- PE Ratio (TTM)
-- - EPS (TTM)
-23.9100 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
140.00
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
tcbiopharm.comRecent News: TCBP
Performance Overview: TCBP
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TCBP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TCBP
Valuation Measures
Market Cap
5.02M
Enterprise Value
4.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.50
Enterprise Value/Revenue
1.83
Enterprise Value/EBITDA
-0.67
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-88.01%
Return on Equity (ttm)
-391.64%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.91M
Diluted EPS (ttm)
-23.9100
Balance Sheet and Cash Flow
Total Cash (mrq)
2.46M
Total Debt/Equity (mrq)
67.08%
Levered Free Cash Flow (ttm)
-12.23M